The U.S. Food and Drug Administration (FDA) confirmed its approval to allow the use of the Drug Appllications, Sabril and Vigabatrin – tablets and oral suspension, to treat infantile spasms in children ages1 month to 2 years and to help treat complex partial seizures in adults.
 
This is the first drug to be approved in the U.S, although it is available in other countries already, for the treatment of a severe type of seizure that usually appears in the first year of life. These infantile spasms weaken the body because of the frequency of daily seizures that are hard to control.
 
During these spasms some babies arch their bodies and stretch their limbs which become stiff. This condition usually occurs after feeding or after waking up.
 
The frequency of these spasms can be as many as several hundreds a day with dozens of clusters. These spasms result from a lot of disorders like, birth injury, metabolic disorders and genetic disorders.
 
Sabril, has also been approved to treat adults suffering with complex partial seizures in combination with other drugs when previous drugs have failed. It was noted that Sabril is not the first-line treatment for these seizures in adults.
 
Lundbeck Inc., a wholly owned subsidiary of H. Lundbeck A/S based in Denmark will market this drug in the market
 
Sabril will have a "black box" warning, the FDA's sternest warning, about the risk of a progressive loss of peripheral vision with potential decrease in visual acuity The FDA states that the risk of vision damage may increase based on the dosage and duration of use, but even the lowest doses of Sabril can cause vision damage.
 
Lundbeck will launch this new drug in the market in the third quarter of 2009, with an extensive risk evaluation and mitigation strategy required by the FDA and created in collaboration with the FDA.